

Camtek Ltd. P.O.Box 544, Ramat Gabriel Industrial Park Migdal Ha'Emek 23150, ISRAEL

Tel: +972 (4) 604-8100 Fax: +972 (4) 644-0523

E-Mail: Info@camtek.com Web site: http://www.camtek.com

CAMTEK LTD.

Moshe Eisenberg, CFO Tel: +972 4 604 8308 Mobile: +972 54 900 7100 moshee@camtek.com

INTERNATIONAL INVESTOR RELATIONS

GK Investor Relations Ehud Helft Tel: (US) 1 646 688 3559 camtek@gkir.com

FOR IMMEDIATE RELEASE

Camtek Announces First Quarter 2020 Results

First quarter revenue \$30.2 million; Second quarter expected between \$36-38 million; Record backlog and strong visibility into the second and third quarters;

MIGDAL HAEMEK, Israel – May 11, 2020 – Camtek Ltd. (NASDAQ: CAMT; TASE: CAMT), today announced its financial results for the first quarter 2020.

Highlights of the First Quarter of 2020

- Revenues of \$30.2 million;
 - O Shipments to customers amounted to approximately \$33 million, however, about \$3 million of this was not recognized due to the Coronavirus related delays in installations and in accordance with our revenue recognition policy;
- GAAP operating income of \$2.9 million; non-GAAP operating income of \$3.7 million;
- GAAP net income of \$2.8 million and non-GAAP net income of \$3.6 million; and
- Operating cash flow of \$1.3 million.

Forward-Looking Expectations

Management expects revenues for the second quarter to be between \$36-38 million. Based on orders on hand, management further expects continued revenue growth and improved profitability in the third quarter.

Management Comment

Rafi Amit, Camtek's CEO, commented, "Camtek is the leader in the 3D metrology arena. Our strategy is to become a leading supplier in the 2D inspection segment as well. In the first half of 2020, we have expanded and strengthened our position in this segment. Some of our customers ordered multiple 2D Inspection machines with basic configuration which affected our average selling price (ASP). We expect these customers to purchase in the future machines for more complex applications with higher ASPs and margins."

Continued Mr. Amit, "We are seeing strong business momentum. We entered the second quarter with record backlog resulting in good visibility and we expect a significant increase in revenue to between \$36-38 million. In the third quarter, we see increased orders for machines with more advanced capabilities and we expect to show an improvement in profitability. It is important to stress that we are

still within the Coronavirus pandemic and it is difficult to anticipate its full magnitude and impact on our business in the coming months."

First Quarter 2020 Financial Results

Revenues for the first quarter of 2020 were \$30.2 million, a decrease of 11% compared with the first quarter of 2019.

Gross profit on a GAAP basis in the quarter totaled \$13.6 million (44.9% of revenues), compared to a gross profit of \$17.2 million (50.5% of revenues) in the first quarter of 2019. Gross profit on a non-GAAP basis in the quarter totaled \$13.6 million (45.2% of revenues), compared to \$17.2 million (50.6% of revenues) in the first quarter of 2019. The decrease in the gross margin in the quarter was due to lower revenue and a less favorable product mix in the quarter.

Operating profit on a GAAP basis in the quarter totaled \$2.9 million (9.5% of revenues), compared to an operating profit of \$6.7 million (19.6% of revenues) in the first quarter of 2019. Operating profit on a non-GAAP basis in the quarter totaled \$3.7 million (12.2% of revenues), compared to \$7.3 million (21.5% of revenues) in the first quarter of 2019.

Net income on a GAAP basis in the quarter totaled \$2.8 million, or \$0.07 per diluted share, compared to net income of \$6.0 million, or \$0.16 per diluted share, in the first quarter of 2019. Net income on a non-GAAP basis in the quarter totaled \$3.6 million, or \$0.09 per diluted share, compared to non-GAAP net income of \$6.7 million, or \$0.18 per diluted share, in the first quarter of 2019.

Cash and cash equivalents and short-term deposits, as of March 31, 2020 were \$90.6 million compared to \$89.5 million as of December 31, 2019. During the quarter, Camtek generated \$1.3 million in operating cash flow.

Conference Call

Camtek will host a conference call today, May 11, 2020, at 9:00am ET.

Rafi Amit, CEO, Moshe Eisenberg, CFO and Ramy Langer, COO will host the call and will be available to answer questions after presenting the results. To participate, please call one of the following telephone numbers a few minutes before the start of the call.

US: 1 888 668 9141 at 9:00am Eastern Time **Israel:** 03 918 0609 at 4:00pm Israel Time

International: +972 3 918 0609

For those unable to participate, the teleconference will be available for replay on Camtek's website at http://www.camtek.com beginning 24 hours after the call.

ABOUT CAMTEK LTD.

Camtek is a leading manufacturer of metrology and inspection equipment and a provider of software solutions serving the Advanced Packaging, Memory, CMOS Image Sensors, MEMS, RF and other segments in the mid end of the semiconductor industry.

Camtek provides dedicated solutions and crucial yield-enhancement data, enabling manufacturers to improve yield and drive down their production costs.

With eight offices around the world, Camtek has best-in-class sales and customer support organization, providing tailor-made solutions in line with customers' requirements.

This press release is available at http://www.camtek.com

This press release may contain projections or other forward-looking statements regarding future events or the future performance of the Company. These statements are only predictions and may change as time passes. Camtek does not assume any obligation to update that information. It is important to note that there is no way to predict how the coronavirus situation will evolve further and impact Camtek's business. Actual events or results may differ materially from those projected, including as a result of changing industry and market trends, reduced demand for our products, the timely development of new products and their adoption by the market, increased competition in the industry, the length and severity of the recent COVID-19 (coronavirus) outbreak, including its impacts across our businesses on demand, operations, and our global supply chains, intellectual property litigation, and price reductions as well as due to risks identified in the documents filed by the Company with the SEC.

This press release provides financial measures that exclude: (i) share based compensation expenses, (ii) discontinued operations, and (iii) Chroma transaction expenses, and are therefore not calculated in accordance with generally accepted accounting principles (GAAP). Management believes that these Non-GAAP financial measures provide meaningful supplemental information regarding our performance. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when evaluating the business internally and therefore felt it is important to make these non-GAAP adjustments available to investors. A reconciliation between the GAAP and non-GAAP results appears in the tables at the end of this press release.

CAMTEK LTD. and its subsidiaries

Consolidated Balance Sheets

March 17 2009 2019 20	(In thousands)		
Assets			
Current assets 49,086 38,047 Cash and cash equivalents 49,086 38,047 Short-term deposits 41,500 51,500 Trade accounts receivable, net 37,141 31,443 Inventories 26,476 23,803 Other current assets 3,083 2,909 Total current assets 157,286 147,702 Fixed assets, net 18,548 18,526 Long term inventory 2,881 2,791 Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 Total assets 180,047 170,369 Liabilities and shareholders' equity 170,369 Current liabilities 16,253 11,334 Total current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Total liabilities 2,187 2,461 Total liabilities 2,187 2,461 <td></td> <td></td> <td></td>			
Cash and cash equivalents 49,086 38,047 Short-term deposits 41,500 51,500 Trade accounts receivable, net 37,141 31,443 Inventories 26,476 23,803 Other current assets 3,083 2,909 Total current assets 157,286 147,702 Fixed assets, net 18,548 18,526 Long term inventory 2,881 2,791 Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 421 4,91 Total assets 180,047 170,369 Liabilities and shareholders' equity 4,213 4,141 Total assets 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,990 34,067 Commitments and contingencies	<u>Assets</u>		_
Short-term deposits 41,500 51,500 Trade accounts receivable, net Inventories 26,476 23,803 Other current assets 3,083 2,909 Total current assets 157,286 147,702 Fixed assets, net 18,548 18,526 Long term inventory 2,881 2,791 Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 Total assets 80,047 170,369 Liabilities and sharcholders' equity 16,253 11,334 Current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,909 34,067 Commitments and contingencies 5 2,187 2,461 40,765.912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 40,765.912 issued shares at March 31, 2020 and 38,649,979 at December 31, 2019 157			
Trade accounts receivable, net Inventories 37,141 31,443 (20) and at December 31, 2019 and solved and s			
Inventories	*		
Other current assets 3,083 2,909 Total current assets 157,286 147,702 Fixed assets, net 18,548 18,526 Long term inventory 2,881 2,791 Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 Total assets 180,047 170,369 Liabilities and shareholders' equity 80,047 170,369 Current liabilities 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Total current liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and 40,742,355 at Shares outstanding at March 31, 2020 and 40,742,355 at Shares outstanding at March 31, 2020 and 38,64			
Total current assets 157,286 147,702 Fixed assets, net 18,548 18,526 Long term inventory 2,881 2,791 Deferred tax asset 745 745 Other assets, net 113 113 Intangible assets, net 474 491 Total assets 180,047 170,369 Liabilities and shareholders' equity 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Total liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies 34,067 Commitments and contingencies 40,090 34,067 Commitments and contingencies 34,067 34,067 Commitments			
Long term inventory 2,881 2,791 Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 Total assets 180,047 170,369 Liabilities and shareholders' equity Current liabilities 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Total liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies 31, 2012 Additional paid-in capital 157 157 Additional paid-in capital 102,202 101,327 Additional paid-in capital 102,202 101,327 Again the saset 113 4,141 Additional paid-in capital 102,202 101,327 Again tax asset 746 746 747 Again tax asset 746 747 747 Again tax asset 747 747 Again tax			
Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 4,213 4,141 Total assets 180,047 170,369 Liabilities and shareholders' equity 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 37,903 31,606 Compterm liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies 40,090 34,067 Commitments and contingencies Shareholders' equity 40,090 34,067 Commitments and contingencies 40,765,912 issued shares at March 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327	Fixed assets, net	18,548	18,526
Deferred tax asset 745 746 Other assets, net 113 113 Intangible assets, net 474 491 4,213 4,141 Total assets 180,047 170,369 Liabilities and shareholders' equity 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 37,903 31,606 Compterm liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies 40,090 34,067 Commitments and contingencies Shareholders' equity 40,090 34,067 Commitments and contingencies 40,765,912 issued shares at March 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327	Long term inventory	2.881	2.791
Intangible assets, net 474 491 4,213 4,141 Total assets 180,047 170,369 Liabilities and shareholders' equity Variety of the current liabilities Trade accounts payable Other current liabilities 16,253 11,334 20,272 Total current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 157 157 157 157 157 157 157 157			
Total assets 4,213 4,141 Liabilities and shareholders' equity Current liabilities Trade accounts payable Other current liabilities 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327			
Total assets 180,047 170,369 Liabilities and shareholders' equity Current liabilities Trade accounts payable Other current liabilities 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity 40,090 34,067 Commitments and contingencies Shareholders' equity 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327	Intangible assets, net	474	491
Liabilities and shareholders' equity Current liabilities Trade accounts payable Other current liabilities 16,253 20,272 Total current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital		4,213	4,141
Current liabilities Trade accounts payable 16,253 11,334 Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327	Total assets	180,047	170,369
Trade accounts payable 16,253 11,334 Other current liabilities 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327	Liabilities and shareholders' equity		
Other current liabilities 21,650 20,272 Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327			
Total current liabilities 37,903 31,606 Long term liabilities 2,187 2,461 Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Vordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327			
Long term liabilities Other long term liabilities 2,187 2,461 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 Additional paid-in capital 102,202 101,327	Other current habilities		20,272
Other long term liabilities 2,187 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Shareholders NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 157 157 Additional paid-in capital 102,202 101,327		37,903	31,606
Total liabilities 2,461 Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 Additional paid-in capital 157 157		2 107	2.461
Total liabilities 40,090 34,067 Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 Additional paid-in capital 157 157	Other long term habilities		
Commitments and contingencies Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 Additional paid-in capital 157 157 157	m + 111 1 1112		
Shareholders' equity Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 Additional paid-in capital 157 157 101,327		40,090	34,067
Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019; 38,673,536 shares outstanding at March 31, 2020 and 38,649,979 at December 31, 2019 Additional paid-in capital 157 157 157	Commitments and contingencies		
December 31, 2019 Additional paid-in capital 157 157 102,202 101,327	Ordinary shares NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2020 and at December 31, 2019; 40,765,912 issued shares at March 31, 2020 and 40,742,355 at December 31, 2019;		
Additional paid-in capital 102,202 101,327		157	157
141,855 138,200		141,855	138,200
Treasury stock, at cost (2,092,376 as of March 31, 2020 and December 31, 2019) (1,898)		(1,898)	(1,898)
Total shareholders' equity 139,957 136,302	Total shareholders' equity	139,957	136,302
Total liabilities and shareholders' equity 180,047 170,369	Total liabilities and shareholders' equity	180,047	170,369

Consolidated Statements of Operations

(in thousands, except share data)			
	Three months ended March 31,		Year ended December 31,
-	2020	2019	2019
-	U.S. dollars		
Revenues	30,179	34,002	134,019
Cost of revenues	16,622	16,846	69,235
Gross profit	13,557	17,156	64,784
Research and development costs Selling, general and administrative expenses	4,130 6,559	3,924 6,575	16,331 26,481
Total operating expenses	10,689	10,499	42,812
Operating income	2,868	6,657	21,972
Financial income, net	375	17	801
Income from continuing operations before incomes taxes	3,243	6,674	22,773
Income tax expense	(463)	(647)	(1,950)
Net income from continuing operations	2,780	6,027	20,823
Income from discontinued operations Income before income tax expense Income tax expense	<u>:</u> _	- -	1,257 (94)
Net income from discontinued operations	<u> </u>		1,163
Net income	2,780	6,027	21,986

	Three months ended March 31, 2020 2019 U.S. dollars		Year ended December 31,
			2019
	C.S. dolla		
Basic earnings from continuing operations	0.07	0.17	0.55
Basic earnings from discontinued operations			0.03
Basic net earnings	0.07	0.17	0.58
Diluted earnings from continuing operations	0.07	0.16	0.54
Diluted earnings from discontinued operations			0.03
Diluted net earnings	0.07	0.16	0.57
Weighted average number of ordinary shares outstanding:			
Basic	38,665	36,476	37,626
Diluted	39,628	37,267	38,432

(In thousands, except share data)

	Three months ended March 31,		Year ended December 31,	
	2020	2019	2019	
	U.S. de	ollars	U.S. dollars	
Reported net income attributable to Camtek Ltd. on GAAP basis	2,780	6,027	21,986	
Share-based compensation	817	645	2,892	
Chroma transaction expenses (1)	-	-	136	
Attributable to discontinued operations	-	-	(1,163)	
Non-GAAP net income	3,597	6,672	23,851	
Non –GAAP net income per share, basic and diluted	0.09	0.18	0.62	
Gross margin on GAAP basis	44.9%	50.5%	48.3%	
Reported gross profit on GAAP basis	13,557	17,156	64,784	
Share-based compensation	86	61	292	
Non- GAAP gross margin	45.2%	50.6%	48.6%	
Non-GAAP gross profit	13,643	17,217	65,076	
Reported operating income attributable to Camtek Ltd. on	2,868	6,657	21,972	
GAAP basis	01=	<i>-</i> 1 =	2.002	
Share-based compensation	817	645	2,892	
Chroma transaction expenses (1)		-	136	
Non-GAAP operating income	3,685	7,302	25,000	

⁽¹⁾ In the second and third quarters of 2019, certain transaction expenses were incurred in relation to the technological cooperation agreement with Chroma. These were recorded under operating expenses.